MONTREAL, QUEBEC -- (MARKET WIRE) -- November 09, 2006 -- MethylGene Inc. (TSX: MYG), today announced that clinical data from one of its Phase I trials (Trial 002) for its histone deacetylase (HDAC) inhibitor, MGCD0103, as well as preclinical data for its lead c-MET, multi-targeted kinase inhibitor, will be presented at two poster sessions at the 18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics,” in Prague, Czech Republic, on November 7th to 10th.
